Advertisement
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

References

  • 1 : Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol2015; 193: 1956. LinkGoogle Scholar
  • 2 : The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol2015; 193: 1963. LinkGoogle Scholar
  • 3 : Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology2007; 70: 1104. Google Scholar
  • 4 : Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol2006; 24: 4448. Google Scholar
  • 5 : Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol2006; 24: 3979. Google Scholar
  • 6 : Standards of medical care in diabetes–2014. Diabetes Care2014; 37: S14. Google Scholar
  • 7 : The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab2001; 86: 4261. Crossref, MedlineGoogle Scholar
  • 8 : The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv2010; 4: 128. Google Scholar
  • 9 : Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med1990; 322: 223. Google Scholar
  • 10 : Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat. J Appl Physiol (1985)2006; 100: 1584. Google Scholar
  • 11 : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002; 346: 393. Google Scholar
  • 12 : GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol2014; 32: 1126. Google Scholar
Advertisement